ESPR — Esperion Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $369.33m
- $548.68m
- $116.33m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -97.2 | -144 | -269 | -234 | -209 |
Depreciation | |||||
Non-Cash Items | 33.8 | 62.1 | 57.2 | 61.7 | 59.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.3 | -4.26 | -52.5 | -3.37 | 13.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -70.3 | -85.2 | -264 | -175 | -135 |
Capital Expenditures | -0.953 | -13.4 | 0 | — | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 65.2 | 34.7 | -50.5 | 8.1 | 42.5 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 64.2 | 21.4 | -50.5 | 8.1 | 42.5 |
Financing Cash Flow Items | 124 | -29.9 | 45.8 | -58.2 | -15.5 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 136 | 202 | 268 | 32.6 | 50.5 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 130 | 138 | -46.1 | -134 | -42.5 |